These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32861505)

  • 21. Vocal Parameters and Self-Perception in Individuals With Adductor Spasmodic Dysphonia.
    Rojas GVE; Ricz H; Tumas V; Rodrigues GR; Toscano P; Aguiar-Ricz L
    J Voice; 2017 May; 31(3):391.e7-391.e18. PubMed ID: 27866691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Common practices in botulinum toxin injection for spasmodic dysphonia treatment: A national survey.
    Shoffel-Havakuk H; Rosow DE; Lava CX; Hapner ER; Johns MM
    Laryngoscope; 2019 Jul; 129(7):1650-1656. PubMed ID: 30582627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dysphonia in performers: toward a clinical definition of laryngology of the performing voice.
    Guss J; Sadoughi B; Benson B; Sulica L
    J Voice; 2014 May; 28(3):349-55. PubMed ID: 24321587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liquid-type Botulinum Toxin Type A in Adductor Spasmodic Dysphonia: A Prospective Pilot Study.
    Cha W; Jang JY; Wang SG; Kang JH; Jo MG
    J Voice; 2017 May; 31(3):378.e19-378.e24. PubMed ID: 27520509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A survey of current practices of physicians who treat adductor spasmodic dysphonia in the U.S.
    Chang CY; Chabot P; Walz CM
    Ear Nose Throat J; 2009 May; 88(5):E18. PubMed ID: 19444777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Socioeconomic Variables of Patients with Spasmodic Dysphonia: A Preliminary Study.
    O'Connell Ferster AP; Sataloff RT; Shewokis PA; Hu A
    J Voice; 2018 Jul; 32(4):479-483. PubMed ID: 28927659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Comparison of Thyroarytenoid Muscle Myectomy and Type II Thyroplasty for Spasmodic Dysphonia.
    Nomoto M; Tokashiki R; Hiramatsu H; Konomi U; Motohashi R; Sakurai E; Toyomura F; Ueda Y; Inoue S; Tsukahara K; Suzuki M
    J Voice; 2015 Jul; 29(4):501-6. PubMed ID: 25737474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and causes of dysphonia in a large treatment-seeking population.
    Cohen SM; Kim J; Roy N; Asche C; Courey M
    Laryngoscope; 2012 Feb; 122(2):343-8. PubMed ID: 22271658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Voice Onset Time for the Word-Initial Voiceless Consonant /t/ in Japanese Spasmodic Dysphonia-A Comparison With Normal Controls.
    Yanagida S; Nishizawa N; Mizoguchi K; Hatakeyama H; Fukuda S
    J Voice; 2015 Jul; 29(4):450-4. PubMed ID: 25944292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.
    Sulica L; Blitzer A; Brin MF; Stewart CF
    Ann Otol Rhinol Laryngol; 2003 Jun; 112(6):499-505. PubMed ID: 12834116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Operative Procedure of Anterior Commissure for Type II Thyroplasty.
    Matsushima K; Isshiki N; Tanabe M; Yoshizaki N; Otsu K; Fukuo A; Matsuura K; Watanabe Y; Sato K
    J Voice; 2018 May; 32(3):374-380. PubMed ID: 28687381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical experience with patients with spasmodic dysphonia and primary Meige syndrome.
    Pedrero-Escalas MF; García-López I; Santiago-Pérez S; Vivancos F; Gavilán J
    Acta Otorrinolaringol Esp (Engl Ed); 2019; 70(1):1-5. PubMed ID: 29716720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Botulinum Toxin and Surgery among Spasmodic Dysphonia Patients.
    van Esch BF; Wegner I; Stegeman I; Grolman W
    Otolaryngol Head Neck Surg; 2017 Feb; 156(2):238-254. PubMed ID: 27803079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
    Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
    J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coprevalence of anxiety and depression with spasmodic dysphonia: a case-control study.
    White LJ; Hapner ER; Klein AM; Delgaudio JM; Hanfelt JJ; Jinnah HA; Johns MM
    J Voice; 2012 Sep; 26(5):667.e1-6. PubMed ID: 22209056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum Toxin Dosing Trends in Spasmodic Dysphonia Over a 20-year Period.
    Namin AW; Christopher KM; Eisenbeis JF
    J Voice; 2017 Jan; 31(1):107-110. PubMed ID: 27005439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient perceptions of factors leading to spasmodic dysphonia: a combined clinical experience of 350 patients.
    Childs L; Rickert S; Murry T; Blitzer A; Sulica L
    Laryngoscope; 2011 Oct; 121(10):2195-8. PubMed ID: 21898448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of type II thyroplasty on adductor spasmodic dysphonia.
    Sanuki T; Yumoto E; Minoda R; Kodama N
    Otolaryngol Head Neck Surg; 2010 Apr; 142(4):540-6. PubMed ID: 20304275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perioperative complications and safety of type II thyroplasty (TPII) for adductor spasmodic dysphonia.
    Mizoguchi K; Hatakeyama H; Yanagida S; Nishizawa N; Oridate N; Fukuda S; Homma A
    Eur Arch Otorhinolaryngol; 2017 May; 274(5):2215-2223. PubMed ID: 28229294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and Voice Characteristics of Laryngeal Pathology in an Italian Voice Therapy-seeking Population.
    Mozzanica F; Ginocchio D; Barillari R; Barozzi S; Maruzzi P; Ottaviani F; Schindler A
    J Voice; 2016 Nov; 30(6):774.e13-774.e21. PubMed ID: 26795968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.